Singular Genomics Systems, Inc. financial data

Symbol
OMIC on Nasdaq
Industry
Laboratory Analytical Instruments
Location
3010 Science Park Road, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 925 % -45.6%
Quick Ratio 74.7 % -33.7%
Debt-to-equity 52.7 % +70.4%
Return On Equity -57.9 % -43.3%
Return On Assets -37.9 % -22.9%
Operating Margin -3.49K % +9.52%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.51M shares -96.6%
Common Stock, Shares, Outstanding 2.51M shares -96.6%
Entity Public Float 49M USD -77.1%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 2.5M shares +3.48%
Weighted Average Number of Shares Outstanding, Diluted 2.5M shares +3.48%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.67M USD +2.74%
Cost of Revenue 4.02M USD +47.8%
Research and Development Expense 43.5M USD -7.16%
Operating Income (Loss) -93M USD +7.04%
Net Income (Loss) Attributable to Parent -86.3M USD +6.85%
Earnings Per Share, Basic 3.23 USD/shares +27.4%
Earnings Per Share, Diluted 3.23 USD/shares +27.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 52.6M USD +58%
Cash, Cash Equivalents, and Short-term Investments 114M USD -40.3%
Inventory, Net 12.4M USD -7.53%
Assets, Current 130M USD -38.4%
Property, Plant and Equipment, Net 12.5M USD -7.22%
Operating Lease, Right-of-Use Asset 42.6M USD -27.1%
Other Assets, Noncurrent 1.07M USD +853%
Assets 187M USD -34.4%
Accounts Payable, Current 1.88M USD -22.6%
Accrued Liabilities, Current 4.89M USD -3.48%
Liabilities, Current 17.6M USD +14%
Operating Lease, Liability, Noncurrent 39.9M USD -32.6%
Other Liabilities, Noncurrent 666K USD -9.88%
Liabilities 63.3M USD -26%
Accumulated Other Comprehensive Income (Loss), Net of Tax 83K USD
Retained Earnings (Accumulated Deficit) -401M USD -27.5%
Stockholders' Equity Attributable to Parent 123M USD -38.1%
Liabilities and Equity 187M USD -34.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.7M USD -32.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 31.6M USD -56.7%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 2.51M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7.88M USD -85.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 53.2M USD +52%
Interest Paid, Excluding Capitalized Interest, Operating Activities 246K USD +13.9%
Deferred Tax Assets, Valuation Allowance 86.2M USD +45%
Deferred Tax Assets, Gross 102M USD +40.4%
Operating Lease, Liability 45.3M USD -32.2%
Depreciation 1.02M USD +28.5%
Payments to Acquire Property, Plant, and Equipment 25K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -86M USD +5.95%
Lessee, Operating Lease, Liability, to be Paid 74.5M USD -38.4%
Property, Plant and Equipment, Gross 23.6M USD +15.1%
Operating Lease, Liability, Current 5.47M USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.81M USD -15.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.37M USD -83.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure +11%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 179M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.69M USD -33.9%
Deferred Tax Assets, Operating Loss Carryforwards 54.3M USD +35.3%
Unrecognized Tax Benefits 2.22M USD +79.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.57M USD -35.1%
Additional Paid in Capital 524M USD +2%
Deferred Tax Assets, Net of Valuation Allowance 15.7M USD +19.5%
Share-based Payment Arrangement, Expense 2.17M USD -22.5%
Interest Expense 1.14M USD +8.14%